Quarterly ResultMay 7, 2026, 04:20 PM
Natera Q1 Revenue +38.8% to $696.6M; Raises 2026 Guidance
AI Summary
Natera reported strong first-quarter 2026 financial results, with total revenues increasing by 38.8% to $696.6 million. The company processed over one million tests for the first time in a single quarter, driven by significant growth in both Women's Health and Oncology segments. Natera also raised its full-year 2026 revenue guidance by $120 million at the midpoint, reflecting confidence in continued adoption of its genetic testing products like Signatera™ and Fetal Focus™. Despite increased operating expenses, the company achieved positive cash inflow of $11.8 million.
Key Highlights
- Total revenues grew 38.8% to $696.6 million in Q1 2026 from $501.8 million in Q1 2025.
- Processed approximately 1,013,600 tests in Q1 2026, an 18.5% increase year-over-year.
- Oncology tests processed increased 54.4% to 258,900 in Q1 2026.
- Gross margin improved to 64.7% in Q1 2026 from 63.1% in Q1 2025.
- Achieved positive cash inflow of approximately $11.8 million in Q1 2026.
- Raised 2026 annual revenue guidance to $2.74 billion - $2.82 billion, an increase of $120 million at midpoint.
- Net loss was $85.1 million, or ($0.60) per diluted share, in Q1 2026.
- Held $1,087.9 million in cash, cash equivalents, and restricted cash as of March 31, 2026.